Genentech blueprints $140M Singapore plant

Genentech is investing $140 million in Singapore to build a new biologics plant to manufacture the eye disease drug Lucentis. The deal marks another coup for Singapore, which just announced that Eli Lilly is building a $150 million lab in the city-state. The new Genentech plant will bring the biotech giant's total investment in Singapore to $500 million, and follows two earlier plant announcements by GlaxoSmithKline and Lonza.

Singapore has been pushing hard to attract biologics manufacturing operations in addition to the drug discovery work already underway. Construction on Genentech's plant is slated to begin in the second quarter of this year.

- rad the report on Genentech's building plans from Channel News Asia

Related Articles:
Lilly plans $150M expansion of Singapore R&D ops. Report
GSK opens $13M drug discovery lab in Singapore. Report
Singapore to spend $8B on biotech R&D. Report

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.